JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow En Espanol
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lorenz, I. H.
Right arrow Articles by Benzer, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lorenz, I. H.
Right arrow Articles by Benzer, A.
Anesth Analg 2000;90:609-613
© 2000 International Anesthesia Research Society

NEUROSURGICAL ANESTHESIA

The Effects of Remifentanil on Cerebral Capacity in Awake Volunteers

Ingo H. Lorenz, MD*, Christian Kolbitsch, MD*, Christoph Hörmann, MD*, Michael Schocke, MD{dagger}, Fritz Zschiegner*, Stephan Felber, MD{dagger}, and Arnulf Benzer, MD*

Departments of *Anesthesia and Intensive Care Medicine and {dagger}Magnetic Resonance Imaging, University of Innsbruck, Austria

Address correspondence and reprint requests to Ingo H. Lorenz, MD, Department of Anesthesia and Intensive Care Medicine, The Leopold-Franzens University of Innsbruck, A-6020 Innsbruck, Anichstr. 35, Austria.

Remifentanil, a short-acting potent µ-opioid agonist proposed for intraoperative analgesia but also for postoperative pain therapy, has not been investigated with regard to the effects of the drug on cerebral capacity in awake humans. We assessed cerebral capacity noninvasively by means of phase-contrast magnetic resonance imaging measurement of systolic cerebrospinal fluid peak velocity in the aqueduct of Sylvius before and during infusion of remifentanil (0.1 µg · kg-1 · min-1 IV) in normocapnic humans. Remifentanil had no significant effect on systolic cerebrospinal fluid peak velocity as compared with baseline (mean ± SD): baseline, -4.3 ± 1.3 cm/s versus remifentanil (0.1 µg · kg-1 · min-1): -4.7 ± 1.0 cm/s. Small-dose remifentanil (0.1 µg · kg-1 · min-1) did not influence cerebral capacity in healthy, awake volunteers free of intracranial pathology.

Implications: Knowledge about the influence of remifentanil on cerebral capacity is crucial before routine use of the drug in neuroanesthesia. Thus, we assessed the influence of remifentanil on cerebral capacity noninvasively by means of phase-contrast magnetic resonance imaging measurement of systolic cerebrospinal fluid peak velocity in the aqueduct of Sylvius in humans.






Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2000 by the International Anesthesia Research Society.